The HOPE ACT Clinical Trial is an NIH study looking at outcomes of HIV+ kidney transplant recipients who may receive either a kidney from a HIV+ donor or an HIV- donor. The trial will determine if receiving a kidney transplant from an HIV positive deceased donor is safe with regards to overall survival and major transplant and major HIV-related complications.
Is this Clinical Trial for You?
The HOPE ACT Clinical Trial study participants should be at least 18 years old and have a known diagnosis of End Stage Kidney failure, be listed for a kidney transplant and diagnosed with a HIV Infection.
How the Clinical Trial Works
This study will evaluate if receiving a kidney transplant from an HIV-infected deceased kidney donor is safe with regards to survival and major transplant-related and HIV-related complications compared to receiving a kidney from an HIV-uninfected deceased kidney donor (HIVD-). Those participants who have accepted an HIVD- organ will be randomized to be followed in the full study or followed in the nested observational group.
Location of the Clinical Trial
Drexel Infectious Disease (Transplant)
216 N. Broad Street
5th Floor, Feinstein Building
Philadelphia, PA 19102
Contact us today for more information!
For more information about this research study, please contact:
Cynthia Gifford-Hollingsworth, DrNP
Principal Investigator: Dong Heun Lee, MD